| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for 600161 from our risk checks.
Beijing Tiantan Biological Products Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥28.16 |
| 52 Week High | CN¥32.73 |
| 52 Week Low | CN¥23.00 |
| Beta | 0.28 |
| 1 Month Change | 3.68% |
| 3 Month Change | 1.44% |
| 1 Year Change | 4.84% |
| 3 Year Change | -5.40% |
| 5 Year Change | 94.25% |
| Change since IPO | 1,273.79% |
Recent News & Updates
We Think Beijing Tiantan Biological Products (SHSE:600161) Can Stay On Top Of Its Debt
Mar 16
Do Beijing Tiantan Biological Products' (SHSE:600161) Earnings Warrant Your Attention?
Mar 01Shareholder Returns
| 600161 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 9.1% | -1.9% | -0.2% |
| 1Y | 4.8% | -26.9% | -17.8% |
Return vs Industry: 600161 exceeded the CN Biotechs industry which returned -26.9% over the past year.
Return vs Market: 600161 exceeded the CN Market which returned -17.8% over the past year.
Price Volatility
| 600161 volatility | |
|---|---|
| 600161 Average Weekly Movement | 5.8% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.4% |
Stable Share Price: 600161 has not had significant price volatility in the past 3 months.
Volatility Over Time: 600161's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1919 | 4,858 | n/a | www.tiantanbio.com |
Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and consulting of blood products in China. Its products include human albumin; intravenous human immunoglobulin; tetanus human immunoglobulin; rabies patient immunoglobulin; hepatitis B human immunoglobulin; freeze-dried intravenous hepatitis B human immunoglobulin; and human prothrombin complex blood products.
Beijing Tiantan Biological Products Co., Ltd. Fundamentals Summary
| 600161 fundamental statistics | |
|---|---|
| Market cap | CN¥46.40b |
| Earnings (TTM) | CN¥1.16b |
| Revenue (TTM) | CN¥5.11b |
39.8x
P/E Ratio9.1x
P/S RatioIs 600161 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600161 income statement (TTM) | |
|---|---|
| Revenue | CN¥5.11b |
| Cost of Revenue | CN¥2.55b |
| Gross Profit | CN¥2.56b |
| Other Expenses | CN¥1.39b |
| Earnings | CN¥1.16b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Apr 26, 2024
| Earnings per share (EPS) | 0.71 |
| Gross Margin | 50.05% |
| Net Profit Margin | 22.79% |
| Debt/Equity Ratio | 0.3% |
How did 600161 perform over the long term?
See historical performance and comparison